Fluvoxamine for the treatment of anxiety disorders in children and adolescents

New England Journal of Medicine

Volumn 344, Issue 17, 2001, Pages 1279-1285

  Pine, Daniel S ^a,c   Walkup, John T ^b   Labellarte, Michael J ^b   Riddle, Mark A ^b   Greenhill, Laurence ^c   Klein, Rachel ^c   Davies, Mark ^c   Sweeney, Michael ^c   Abikoff, Howard ^d   Hack, Sabine ^d   Klee, Brian ^d   McCracken, James ^e   Bergman, Lindsey ^e   Piacentini, John ^e   March, John ^f   Compton, Scott ^f   Robinson, James ^g   O'Hara, Thomas ^g   Baker, Sherryl ^g   Vitiello, Benedetto ^a   Ritz, Louise ^a   Roper, Margaret ^a   more..

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY   (United States)

^g Nathan Kline Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL DISCOMFORT; ADOLESCENT; ANXIETY NEUROSIS; APPETITE DISORDER; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEPARATION ANXIETY; SKIN IRRITATION; SLEEP DISORDER; SOCIAL PHOBIA; SORE THROAT; SYMPTOM; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; ANXIETY, SEPARATION; CHILD; FEMALE; FLUVOXAMINE; HUMANS; MALE; PHOBIC DISORDERS; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS;

EID: 0035953646     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200104263441703     Document Type: Article

References (46)

1. Anxiety disorders
2. Childhood anxiety disorders
3. The NIMH Diagnostic Interview Schedule for Children version 2.3 (DISC-2.3): Description, acceptability, prevalence rates, and performance in the MECA Study: Methods for the Epidemiology of Child and Adolescent Mental Disorders Study
4. Who gets treated? Factors associated with referral in children with psychiatric disorders
5. Treatment typically provided for comorbid anxiety disorders
6. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial
7. The treatment of anxiety disorders in children and adolescents
8. The significance of self-reported anxious symptoms in first grade children: Prediction to anxious symptoms and adaptive functioning in fifth grade
9. Predictors of severity of absenteeism in children with anxiety-based school refusal
10. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders
11. Adolescent outcomes of childhood disorders: The consequences of severity and impairment
12. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis
13. Update on the diagnosis and treatment of social anxiety disorder
14. Medication treatments for panic disorder and social phobia
15. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial
16. Nontricyclic antidepressants: Current trends in children and adolescents
17. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
18. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents
19. Fluoxetine for childhood anxiety disorders
20. Assessment is sues in treatment research of pediatric anxiety disorders: What is working, what is not working, what is missing, and what needs improvement
21. The Pediatric Anxiety Rating Scale (PARS): A reliability study
22. A children's global assessment scale (CGAS)
23. Clonazepam in childhood anxiety disorders
24. Multi-center trial of paroxetine and imipramine in the treatment of adolescent depression
25. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data
26. Hyperactive children treated with stimulants: Is cognitive training a useful adjunct?
27. Imipramine treatment of children with separation anxiety disorder
28. The Multidimensional Anxiety Scale for Children (MASC): Factor structure, reliability, and validity
29. The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics
30. Gender and the comparison of self and observer ratings of anxiety and depression in adolescents
31. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: Application to the NIMH Treatment of Depression Collaborative Research Program dataset
32. Empirically supported psychological therapies
33. Cognitive-behavioral treatment of school phobia
34. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
35. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid?
36. Users' grades to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients?
37. Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
38. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life
39. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus
40. The role of corticotropin-releasing factor-norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress
41. Long-term behavioral and neuroendocrine adaptations to adverse early experience
42. Cerebrospinal fluid concentrations of somatostarin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions
43. Validity of clinical trials of antidepressants